PVLAHealthcare · BiotechnologyThe 16 Wall Street analysts covering Palvella Therapeutics, Inc. hold a median 12-month price target of $232 — +43.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Palvella Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PVLA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +43.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Chardan Capital | Maintains | Buy | $240 |
| 16 Oct 2026 | William Blair | Initiates | Outperform | — |
| 16 Oct 2026 | William Blair | Initiates | Outperform | — |
| 12 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $270 → $246 |
| 21 Sept 2026 | Chardan Capital | Maintains | Buy | — |
| 21 Sept 2026 | Chardan Capital | Maintains | Buy | $240 |
| 21 May 2026 | Chardan Capital | Maintains | Buy | $240 |
| 21 May 2026 | Chardan Capital | Maintains | Buy | — |
| 21 May 2026 | Stephens & Co. | Reiterates | Overweight | — |
| 21 May 2026 | Stephens & Co. | Reiterates | Overweight | $220 |
| 12 May 2026 | Stephens & Co. | Initiates | Overweight | — |
| 31 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 24 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 25 Feb 2026 | BTIG | Maintains | Buy | — |
| 25 Feb 2026 | Mizuho | Maintains | Outperform | — |
| 24 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Jan 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PVLA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Palvella Therapeutics, Inc. returned +116.2% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 48% of US stocks
Cheaper than 9% of US stocks
Cheaper than 95% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Palvella Therapeutics, Inc. has a market value of $2.1B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$61.7M.
Free cash flow in the twelve months to 30 June 2026: −$36.5M.
Trailing P/E: 13.7×; forward P/E: −19.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Palvella Therapeutics, Inc. employs 29 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Palvella Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Palvella Therapeutics announced that members of its management team will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 9:20 a.m. ET.
Why it matters — The presentation is a company event that PVLA watchers may follow for management updates.
Palvella Therapeutics announced it will report its third-quarter 2026 financial results before market open on November 5, 2026. The company will host a conference call for the results and a corporate update.
Why it matters — PVLA watchers can note the date and timing of the company’s quarterly results and corporate update.
Palvella Therapeutics announced that the FDA accepted the QTORIN™ rapamycin NDA and granted it Priority Review, with a February 28, 2027 PDUFA target action date. The company said the therapy could become the first FDA-approved treatment for microcystic lymphatic malformations.
Why it matters — The regulatory milestone and target action date are relevant to PVLA watchers tracking development of a potential treatment for this rare disease.
Palvella CFO Matt Korenberg said the company is preparing for a potential commercial launch of QTORIN rapamycin while advancing other rare skin and vascular anomaly programs.
Why it matters — The comments outline PVLA’s stated commercial preparation and ongoing pipeline development.
Palvella Therapeutics said it will present Phase 3 SELVA and Phase 2 TOIVA results, along with new pediatric analyses, at the 2026 PeDRA Annual Conference. The announced SELVA analyses highlight improvements in overall disease severity and a blinded combined score assessing lesion height, vesicle appearance, and leaking or bleeding.
Why it matters — The presentations will provide PVLA watchers with updates on clinical results and pediatric analyses for the company’s programs.
The 16 Wall Street analysts covering Palvella Therapeutics, Inc. have a median 12-month price target of $232, with estimates ranging from $205 to $267. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Palvella Therapeutics, Inc., 16 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palvella Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Palvella Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +43.0% from the last close, and Ticker Nerd's factor model ranks Palvella Therapeutics, Inc. 36 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Palvella Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PVLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $205 to $267 over the next 12 months.
Palvella Therapeutics, Inc. returned +116.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved treatment options.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference". Palvella Therapeutics announced that members of its management team will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 9:20 a.m. ET.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved treatment options. The company centers its work on dermatology-focused rare disease programs, using its proprietary QTORIN platform to create topical therapies designed for localized delivery in difficult-to-treat conditions. Its current pipeline includes product candidates being studied for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, reflecting a focus on genetically driven and orphan skin disorders. Palvella Therapeutics serves the rare disease and specialty dermatology markets, where targeted medicines can address conditions that are often chronic, burdensome, and underserved by existing therapies. Palvella Therapeutics, Inc. is headquartered in Wayne, Pennsylvania.
CEO Mr. Wesley H. Kaupinen · 29 employees · United States · https://palvellatx.com
